New peptide policy heads to White House for final sign-off

By Laura DiAngelo, MPH

A long-anticipated FDA policy on compounded peptides is undergoing White House review, potentially setting the stage for changes to how the agency approaches access and enforcement. The interim policy follows growing attention to peptide compounding and questions about the appropriate balance between patient access and regulatory oversight.
Although the framework’s details remain unclear, its development could provide an early indication of FDA’s broader plans for regulating compounded peptides.

This AgencyIQ analysis examines the regulatory history behind the pending policy, the questions still unresolved and what its eventual release could signal for the future of peptide compounding.

Fill out the form to read the full analysis.